Sint Franciscus Vlietland Groep Stichting — Clinical Trial Site

93 Registered trials

45 Currently recruiting

Organisation

Sint Franciscus Vlietland Groep Stichting

Location

Rotterdam, Netherlands

Identifier

ORG-100041036

Address

Vlietlandplein 2, 3118 JH, Netherlands

Departments

-
#2203: oncology
Cardiology
Dep of Internal Diseases
Dep of Lung Diseases
Departement of Oncology
Department of Gastroenterology & hepatology
Department of Internal Medicine
Department of Oncology
Department of Surgical Oncology
Emergency Department
Endocrinologie
Franciscus Gasthuis
Franciscus Gasthuis & Vlietland, Locatie Gasthuis
Franciscus_Internal Medicine
Gastro-enterology
Gastroenterology
Gastroenterology & Hepatology
Gynaecology
hematology
Intensive Care
Intensive care unit
Internal medicine
Internal Medicine / Dialysis
Internal Oncology
interne geneeskunde
interne geneeskunder
Longgeneeskunde
Longziekten
MDL
Medical Oncology
N/A
Neurologie
Neurology
Obstetrics & Gynecology
Oncologie
Oncologie Centrum
Oncologisch Centrum
Oncology
Otorhinolaryngology
Paediatric Gastroenterology
Pediatrics
Pharmacy
Poli Cardiology
Prostaatcentrum
Pulmonology
Pulmonology / Respiratory medicine
Reproductive medicine and gynecology
Rheumatology
Stichting Sint Franciscus Vlietland Groep
Surgery

Clinical trials at this site (93)

Search interface

SAFEST Not authorised

2022-502059-79-00 Ischemic stroke or transient ischemic attack 6
Avelumab Short Maintenance Trial Pending

2024-512975-11-01 urothelial cancer 11
MEDFAST-study Pending

2024-519774-40-00 People with a Body Mass Index (BMI) of 30 kg/m2 or more 6
Adjuvant Pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after treatment with chemotherapy an… Pending

2025-524229-41-00 Triple negative breast cancer 5
A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease Recruiting

2025-524001-33-00 Graves’ Disease 4 2026-05-22
Study for frail patients with newly diagnosed multiple myeloma treated with Daratumumab in combination with Teclistamab and Talquetamab. Recruiting

2024-520433-76-00 Newly Diagnosed Multiple Myeloma 4 2026-01-08
Adjuvant chemotherapy for prevention of recurrence in patients with detectable ctDNA after surgery in high-riskrectal cancer. Recruiting

2024-517700-12-00 Rectal cancer 5 2025-12-10
A study to investigate airway inflammation with dupilumab subcutaneously in participants aged ≥40 to ≤85 years with chronic obstructive pulm… Recruiting

2025-521268-37-00 Respiratory tract diseases 6 2025-11-25
T3-4-Hypo trial Recruiting

2024-513883-24-00 Hypothyroidism Triiodothyronine Quality of Life Persist 5 2025-11-02
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting

2024-518296-56-00 Crohn’s Disease 5 2025-09-29
Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting

2022-500273-14-00 Atherosclerotic cardiovascular disease in patients with 10 2023-07-17
A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-034) Recruiting

2024-516993-31-00 Renal Cell Carcinoma 5 2026-05-11
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney D… Recruiting

2025-523123-22-00 Chronic Kidney Disease 5 2026-05-07
HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting

2025-523717-29-00 HFpEF or HFmrEF and obesity 5 2026-04-28
Optimization of pain management for acute renal colic in the Emergency Department – The OPTIMIZED trial Recruiting

2025-521316-19-00 Urolithiasis 6 2026-04-20
A Study to Evaluate Brenipatide Compared with Placebo in Adult Participants with Uncontrolled Moderate to Severe Asthma Recruiting

2025-522640-41-00 Asthma 4 2026-02-13
Randomized Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carc… Recruiting

2024-515023-11-00 Metastatic Clear Cell Renal Cell Carcinoma 5 2026-01-22
Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting

2025-521382-27-00 Moderately to Severely Active Crohn's Disease 10 2025-12-04
A Phase 2b Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Graves' Disease Recruiting

2025-521920-31-00 Graves’ Disease 4 2025-11-21
A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advan… Recruiting

2025-520566-22-00 Hormone Receptor-Positive, HER2-Negative Advanced/Metas 5 2025-11-10
An open-label study of JSB462 (luxdegalutamide) in combination with abiraterone in adult male patients with metastatic hormone-sensitive pro… Recruiting

2024-520156-22-00 Metastatic hormone-sensitive prostate cancer 4 2025-10-08
Shorter weaning from invasive ventilation with levosimendan: a randomized, double-blind, multicenter study in critically ill patients. Recruiting

2024-518810-23-00 Failure to wean from invasive ventilation. 6 2025-09-17
Continuing ovulation induction with letrozole versus switching to gonadotropins in women with polycystic ovary syndrome (MOVIN-II study) Recruiting

2024-519354-36-00 Polycystic ovary syndrome (PCOS) 6 2025-08-01
A pHase III cluster randomIsed controlled, cross-over, non-inferiority Trial of a short course, High dose AntimicRobials vs conventional dos… Recruiting

2024-514730-21-00 Bacterial infections and mycoses 5 2025-07-01